Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactasin (乳酶生) is a live biotherapeutic product containing dried preparations of live bacteria, primarily *Enterococcus faecalis* (formerly *Streptococcus faecalis*). It functions by decomposing carbohydrates in the intestine to produce lactic acid, which increases the acidity of the intestinal environment. This acidic shift inhibits the growth and reproduction of putrefactive bacteria, prevents excessive intestinal fermentation, and reduces gas production. It is indicated for the treatment of digestive disorders such as indigestion, abdominal distension, and diarrhea, particularly in children, caused by dietary imbalance. It also serves as an auxiliary treatment for intestinal flora imbalance and secondary infections resulting from prolonged antibiotic use. [1, 2, 3, 5, 7, 8, 9, 11, 12, 15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lactasin.